Disease Clusters?
Groups of diseases that share a large number of curated genes with each other, computed via label propagation over the shared-gene similarity graph. See also Shared-Gene Disease Pairs for pairwise comparisons.
← Back to all clusters
Cluster 246
7
Diseases
16
Unique genes
0.193
Avg. similarity score
Leukocyte disorders
Most-connected disease (5 links)
Disease
Pinned (dragged)
Node size = connections within this cluster · edge thickness = similarity strength · hover an edge for its details ·
click a node to select it and show its pairs below (double-click or Ctrl/⌘-click opens the disease page) ·
drag a node to pin it in place · scroll/pinch to zoom.
Leukocyte disorders
Conjunctivitis
hypoplasminogenemia
Laryngeal disease
Splenic disease
FAS-related autoimmune lymphoproliferative immune disorder
Developmental delay with autism spectrum disorder
Member diseases (most connected first ‐ the cluster's core)
| Disease ⇵ | Connections in cluster ⇵ | Significant partners ⇵ | Curated genes ⇵ |
|---|---|---|---|
| Leukocyte disorders | 5 | 5 | 3 |
| Conjunctivitis | 4 | 4 | 2 |
| hypoplasminogenemia | 4 | 4 | 1 |
| Laryngeal disease | 3 | 3 | 6 |
| Splenic disease | 3 | 3 | 9 |
| FAS-related autoimmune lymphoproliferative immune disorder | 2 | 2 | 1 |
| Developmental delay with autism spectrum disorder | 1 | 1 | 1 |
Top shared genes (genes linked to 2+ member diseases)
| Gene ⇵ | Member diseases ⇵ | Linked diseases |
|---|---|---|
| PLG | 5 / 7 | Conjunctivitis, hypoplasminogenemia, Laryngeal disease, Leukocyte disorders and 1 more |
| FAS | 3 / 7 | FAS-related autoimmune lymphoproliferative immune disorder, Leukocyte disorders, Splenic disease |
| HERC2 | 2 / 7 | Conjunctivitis, Developmental delay with autism spectrum disorder |
What do these columns mean?
- Connections in cluster
- How many other members this disease has a shared-gene link to (the node size in the network above). The most-connected diseases are the cluster's core.
- Significant partners
- How many of those links are statistically significant (FDR q < 0.05).
- Curated genes
- Distinct curated genes linked to that disease in GeDiPNet.
- Member diseases (Top shared genes)
- How many of this cluster's diseases are linked to the gene, out of the cluster's total. Genes shared by many members are the most direct explanation of why they group together.
- Overlap genes (x / y)
- x = genes shared between this cluster and the pathway/GO term; y = that pathway/GO term's total gene count. A higher x relative to y (and to the cluster's own size) means a tighter biological match.
- Cluster gene count
- Total distinct genes across every disease in this cluster -- the "n" used in the significance test below.
- Fold enrichment
- Observed overlap divided by the overlap expected by chance, given the cluster's gene count, the pathway/term's size and the gene universe tested. 5× means five times more shared genes than random. Tells strong hits apart when q-values are all vanishingly small.
- P-value / FDR q-value
- Is this pathway/GO term's overlap with the cluster more than chance? Upper-tail hypergeometric test, Benjamini-Hochberg corrected across every tested pathway/term (prefer the q-value -- it accounts for testing many at once).
- Shared genes (Pairs within this cluster)
- Number of curated genes the two diseases in that row have in common.
- Similarity score (Pairs within this cluster)
- Jaccard-based gene overlap between the two specific diseases in that row -- same metric as the main Shared-Gene Disease Pairs page.
Enriched Pathways (why this cluster is grouped, biologically)
| Pathway ⇵ | Source ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| Aromatic amines can be N-hydroxylated or N-dealkylated by CYP1A2 | Reactome | 1 / 1 | 751× | 1.33e-3 | 1.68e-2 ✓ sig. |
| APC truncation mutants are not K63 polyubiquitinated | Reactome | 1 / 1 | 751× | 1.33e-3 | 1.68e-2 ✓ sig. |
| Influenza A | KEGG | 3 / 173 | 13.0× | 1.43e-3 | 1.78e-2 ✓ sig. |
| Chemical carcinogenesis - receptor activation | KEGG | 3 / 215 | 10.5× | 2.67e-3 | 2.83e-2 ✓ sig. |
| Leishmaniasis | KEGG | 2 / 78 | 19.2× | 4.71e-3 | 4.21e-2 ✓ sig. |
| Biosynthesis of protectins | Reactome | 1 / 4 | 188× | 5.32e-3 | 4.56e-2 ✓ sig. |
| Complement and coagulation cascades | KEGG | 2 / 88 | 17.1× | 5.96e-3 | 4.92e-2 ✓ sig. |
| FasL/ CD95L signaling | Reactome | 1 / 5 | 150× | 6.64e-3 | 5.28e-2 |
| Staphylococcus aureus infection | KEGG | 2 / 99 | 15.2× | 7.49e-3 | 5.69e-2 |
| Caffeine metabolism | KEGG | 1 / 6 | 125× | 7.97e-3 | 5.96e-2 |
| Biosynthesis of maresin-like SPMs | Reactome | 1 / 6 | 125× | 7.97e-3 | 5.96e-2 |
| Interleukin-4 and Interleukin-13 signaling | Reactome | 2 / 108 | 13.9× | 8.86e-3 | 6.38e-2 |
| Th17 cell differentiation | KEGG | 2 / 109 | 13.8× | 9.01e-3 | 6.45e-2 |
| Aryl hydrocarbon receptor signalling | Reactome | 1 / 7 | 107× | 9.29e-3 | 6.56e-2 |
| Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET) | Reactome | 1 / 8 | 93.8× | 1.06e-2 | 7.12e-2 |
Enriched GO Terms (Biological Process, a second line of biological evidence)
| GO term ⇵ | GO ID ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| proteasome-mediated ubiquitin-dependent protein catabolic process | GO:0043161 | 4 / 343 | 13.6× | 1.70e-4 | 4.51e-3 ✓ sig. |
| cell adhesion | GO:0007155 | 5 / 665 | 8.8× | 1.77e-4 | 4.64e-3 ✓ sig. |
| microglial cell activation | GO:0001774 | 2 / 28 | 83.4× | 2.56e-4 | 6.02e-3 ✓ sig. |
| positive regulation of apoptotic signaling pathway | GO:2001235 | 2 / 37 | 63.1× | 4.50e-4 | 8.90e-3 ✓ sig. |
| positive regulation of nitric oxide biosynthetic process | GO:0045429 | 2 / 42 | 55.6× | 5.80e-4 | 1.06e-2 ✓ sig. |
| cell-cell adhesion | GO:0098609 | 3 / 218 | 16.1× | 7.84e-4 | 1.29e-2 ✓ sig. |
| toxin biosynthetic process | GO:0009403 | 1 / 1 | 1,168× | 8.56e-4 | 1.36e-2 ✓ sig. |
| nuclear receptor-mediated mineralocorticoid signaling pathway | GO:0031959 | 1 / 1 | 1,168× | 8.56e-4 | 1.36e-2 ✓ sig. |
| symbiont-induced defense-related programmed cell death | GO:0034050 | 1 / 1 | 1,168× | 8.56e-4 | 1.36e-2 ✓ sig. |
| interleukin-35-mediated signaling pathway | GO:0070757 | 1 / 1 | 1,168× | 8.56e-4 | 1.36e-2 ✓ sig. |
| extrinsic apoptotic signaling pathway | GO:0097191 | 2 / 57 | 41.0× | 1.07e-3 | 1.57e-2 ✓ sig. |
| tumor necrosis factor-mediated signaling pathway | GO:0033209 | 2 / 60 | 38.9× | 1.18e-3 | 1.67e-2 ✓ sig. |
| alkaloid metabolic process | GO:0009820 | 1 / 2 | 584× | 1.71e-3 | 2.07e-2 ✓ sig. |
| response to interleukin-12 | GO:0070671 | 1 / 2 | 584× | 1.71e-3 | 2.07e-2 ✓ sig. |
| positive regulation of growth factor dependent skeletal muscle satellite cell proliferation | GO:1902728 | 1 / 2 | 584× | 1.71e-3 | 2.07e-2 ✓ sig. |
Pairs within this cluster, by significance
| Disease A ⇵ | Disease B ⇵ | Similarity score ⇵ | Shared genes ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| Leukocyte disorders | Splenic disease | 0.182 | 2 | 9.11e-7 | 5.67e-6 ✓ sig. |
| Conjunctivitis | Developmental delay with autism spectrum disorder | 0.333 | 1 | 1.30e-4 | 3.90e-4 ✓ sig. |
| Conjunctivitis | hypoplasminogenemia | 0.333 | 1 | 1.30e-4 | 3.90e-4 ✓ sig. |
| FAS-related autoimmune lymphoproliferative immune disorder | Leukocyte disorders | 0.250 | 1 | 1.95e-4 | 5.28e-4 ✓ sig. |
| hypoplasminogenemia | Leukocyte disorders | 0.250 | 1 | 1.95e-4 | 5.28e-4 ✓ sig. |
| Conjunctivitis | Leukocyte disorders | 0.200 | 1 | 3.90e-4 | 8.52e-4 ✓ sig. |
| hypoplasminogenemia | Laryngeal disease | 0.143 | 1 | 3.90e-4 | 8.52e-4 ✓ sig. |
| FAS-related autoimmune lymphoproliferative immune disorder | Splenic disease | 0.100 | 1 | 5.84e-4 | 1.14e-3 ✓ sig. |
| hypoplasminogenemia | Splenic disease | 0.100 | 1 | 5.84e-4 | 1.14e-3 ✓ sig. |
| Conjunctivitis | Laryngeal disease | 0.125 | 1 | 7.79e-4 | 1.39e-3 ✓ sig. |
| Laryngeal disease | Leukocyte disorders | 0.111 | 1 | 1.17e-3 | 1.88e-3 ✓ sig. |